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and Frederick M Hecht, MD5
Abstract
Background: We describe the study design and protocol of a pragmatic randomized controlled trial (RCT) Acupressure
for Children in Treatment for a Childhood Cancer (ACT-CC).
Objective: To describe the feasibility and effectiveness of an acupressure intervention to decrease treatment-related symp-
toms in children in treatment for cancer or recipients of a chemotherapy-based hematopoietic stem cell transplant (HSCT).
Design: Two-armed RCTs with enrollment of 5 to 30 study days.
Setting: Two pediatric teaching hospitals.
Patients: Eighty-five children receiving cancer treatment or a chemotherapy-based HSCT each with 1 parent or caregiver.
Intervention: Patients are randomized 1:1 to receive either usual care plus daily professional acupressure and caregiver
delivered acupressure versus usual care alone for symptom management. Participants receive up to 20 professional treatments.
Main Outcome: A composite nausea/vomiting measure for the child.
Secondary Outcomes: Child’s nausea, vomiting, pain, fatigue, depression, anxiety, and positive affect.
Parent Outcomes: Depression, anxiety, posttraumatic stress symptoms, caregiver self-efficacy, and positive affect.
Feasibility of delivering the semistandardized intervention will be described. Linear mixed models will be used to compare
outcomes between arms in children and parents, allowing for variability in diagnosis, treatment, and age.
Discussion: Trial results could help childhood cancer and HSCT treatment centers decide about the regular inclusion of
trained acupressure providers to support symptom management.
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Introduction
Background and Rationale
Despite advances in pharmacologic symptom manage-
ment, most children with cancer1,2 or receiving a hema-
topoietic stem cell transplant (HSCT)3–6 suffer from
multiple treatment-related symptoms including nausea,
vomiting,7 pain,8 and fatigue.3 Pharmacologic symptom
management can be effective, but can have side effects
that decrease quality of life.9,10 Symptom distress is an
important predictor of poor health-related quality of life
among children treated for cancer11 or receiving
HSCT.6,12 Severe symptoms can result in interruptions
in planned treatment, dose reductions, or other therapy
changes with the potential to compromise survival.13,14
A systematic review documented frequent undertreated
symptoms during oncology and HSCT treatment.1
A growing body of high-quality evidence from large
meta-analyses and systematic reviews of adult acupuncture
point stimulation supports the use of acustimulation for
the management of adult pain,15–19 headache,20–22 postop-
erative nausea/vomiting (PONV),23 presurgery anxiety,
chemotherapy-related nausea/vomiting (CINV),24–35
cancer-related pain,24,36 cancer-related anxiety,32,37,38
chemotherapy-related fatigue,38,39 and cancer treatment-
related symptoms.24 (The term acustimulation is used
throughout the protocol and refers to the use of needles,
laser, or pressure stimulation.) A National Institutes of
Health (NIH) Consensus Conference assessed acupunc-
ture as effective in reducing CINV and PONV.40
Compared to pharmacologic symptom management
alone, in adults, acustimulation may provide equivalent41
or superior30 symptom relief and decreased the use of
rescue antiemetics and opioids.29
Fewer studies support the use of acustimulation in
children. Systematic reviews reported that acupuncture
decreased pain,42 and a Cochrane review reported
decreased PONV.41 Three randomized controlled trials
(RCTs) reported no statistically significant effect of
acupressure on CINV43–45 or PONV.46,47 Two well-
designed, but small RCTs of children receiving highly
emetogenic chemotherapy for treatment of a childhood
cancer reported decreased nausea and vomiting48,49 as
well as reduced the use of antiemetic medications follow-
ing acupuncture.50 An RCT of children with leukemia
showed decreased postchemotherapy fatigue with the
application of acupressure to a single point (St36), but
results lasted less than 24 hours.51 A review article of
acustimulation for nausea, vomiting, or rescue antiemet-
ics describes the quality of evidence as low but having
nonsignificant moderate effect sizes (ESs) in acupuncture
versus sham in children.52 Studies consistently report few
side effects and a strong safety profile.41,42,48,53 Most
acustimulation studies described side effects from
acupuncture (not acupressure), and these included pain
on needle insertion, redness, irritation, bleeding, swell-
ing, itching, or fatigue.42,48,53
In its supportive care guidelines The Children’s
Oncology Group (COG) states “that acupuncture, acu-
pressure . . .may be effective in children receiving anti-
neoplastic agents” to reduce CINV.54 However, the
strength of the COG recommendation is rated as
“weak” and the quality of evidence is categorized as
“very low.”54 Acustimulation has the potential strengths
of being safe, having few side effects, and addressing
multiple symptoms with one treatment. However, the
majority of systematic reviews have concluded that addi-
tional high-quality trials are needed among children to
assess the effectiveness of acustimulation to reduce pain,
nausea, and vomiting in general populations,42,55–59 as
well as in childhood cancer.29,30,60,61
Trial Objectives/Aims
The primary objective of Acupressure for Children in
Treatment for a Childhood Cancer (ACT-CC) is to
describe the feasibility, benefits, and risks of an acupres-
sure intervention plus usual care versus usual care alone
for symptom management in children in treatment for a
childhood cancer and/or receiving a chemotherapy-based
HSCT. Aim 1 assesses whether patients in the acupressure
arm, compared to usual care alone arm, will report
decreased nausea/vomiting (primary outcome) and
improved management of treatment-related symptoms
such as nausea, vomiting (separately), pain interference
and intensity, fatigue, anxiety, depression, and greater
positive affect (secondary outcomes). It is hypothesized
that rescue antiemetic and analgesic use will be lower in
the acupressure arm and that greater acupressure dose
will lead to greater improvement of primary and second-
ary outcomes. Aim 2 investigates whether parent involve-
ment in the delivery of acupressure reduces posttraumatic
stress symptoms, anxiety and depression, and increases
positive affect and caregiving self-efficacy.
This protocol manuscript is based on the SPIRIT
(Standard Protocol Items: Recommendations for
Interventional Trials) guidelines to ensure comprehen-
siveness of reporting62 with recommended additions
from the SPIRIT protocol to Traditional Chinese
Medicine (TCM).63 The study protocol will be made
available on the ACT-CC study website once the trial
is complete.
Trial Design
This is a 2.5-year pragmatic RCT among children receiv-
ing treatment for a childhood cancer or a HSCT.
We will enroll 85 dyads consisting of a child with
a parent/caregiver for a total of 170 participants. Study
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staff and health-care providers are blinded to study arm
assignment. Participants will be randomized 1:1 into the
2 arms and will be followed for up to 30 days of hospital-
based oncology or HSCT treatment (continuous or inter-
mittent days) within 2 calendar months from enrollment.
If a patient finishes treatment before 30 study days (ie,
end of stem cell transplant hospitalization), the study
enrollment period ends. Children in Arm A will receive
professional acupressure 5 days/week along with usual
care, and their parent/caregiver will be trained in how
to provide additional acupressure to manage symptoms.
Arm B participants will receive usual care alone. (The
caregiver will be trained in how to provide acupressure
at the end of study participation.)
Stakeholder Involvement
Stakeholders were engaged with the original design for
the pilot study during study development, and have
ongoing involvement in the study implementation
(recruitment, outreach, intervention, and reviewing
patient materials). Stakeholders will continue their
involvement in the interpretation of the results and in
discussions on framing or interpretation of findings.
Methods: Participants, Intervention,
and Outcomes
Study Setting
Inpatients and outpatients are enrolled from a United
States, Northern California Pediatric Teaching
Hospital with 2 sites. Patients are enrolled from
hematology-oncology, neuro-oncology, or HSCT units.
Participants’ Eligibility Criteria
The ACT-CC study aims to enroll 85 patients, most with
1 caregiver. Recruitment started in October 2017.
Inclusion criteria for ACT-CC require that the child is
either receiving treatment for childhood cancer (curative
or supportive care) or a chemotherapy-based HSCT
(nonmalignant central nervous system tumors are con-
sidered a childhood cancer); be age 5 through 24 years
old; be receiving hospital-based treatment (inpatient or
outpatient); English or Spanish speaking; and availabil-
ity and willingness of a parent or caregiver to deliver
acupressure for patients aged 5 to 17 years. (For
young adults aged 18–24 years, participation of a
parent, close friend, or family member/caregiver is pre-
ferred but not required.) Children are excluded if the
treating oncologist, health-care provider, or a study
investigator advises against study participation for phys-
ical health, mental health (parent or child), or logistical
reasons. Examples of exclusion reasons include when the
health-care provider thinks participation might be bur-
densome, there are serious mental health issues for child
or caregiver, family stress, a child is receiving a radioac-
tive treatment and is in isolation, or hospital visits are
not long enough or frequent enough to provide the
intervention.
Intervention
The protocol is based on adherence to the STRICTA
reporting guidelines (Standards for Reporting
Interventions in Clinical Trials of Acupuncture)64
which are an extension of the CONSORT Statement65
and the CONSORT guidelines for nonpharmacologic
interventions.66 The STRICTA guidelines were developed
to improve the completeness and transparency of report-
ing acupuncture interventions (see Table 1).64
Acupoint treatment order. Most points used are located
distal to the elbows or knees. Treatment is applied
based on primary symptom/complaint using standard
points (termed “platform points”) prescribed for each
symptom. Additional points (þ) are included in the pro-
tocol and can be chosen based on secondary symptoms,
experience, and TCM diagnosis (see Table 2).76,77
Acupressure points are applied in the following order:
• Upper limbs—yin (medial) side (distal to proximal)
then yang (outer) side (distal to proximal)
• Lower limbs—yin side (distal to proximal) then yang
side (distal to proximal)
• Prone (face down)—lower torso working up to head
• Supine (face up)—abdomen working up to chest and
then face
Delivery of Intervention for Each Group
Intervention precautions. Before proceeding with the acu-
pressure session, the provider verifies platelet counts,
assesses for skin breakdown associated with graft
versus host disease (GVHD), or infection precautions.
If platelet counts are <10 000/mL, usual supportive
care guidelines recommend a transfusion. If the patient
has not received a transfusion, the acupressure provider
instructs parents to defer acupressure until platelets
recover. Professional acupressure will continue to be
delivered by the practitioner using gentle touch as per
recommendations from the oncology team. In the case of
infection precautions, the acupressure provider follows
designated institutional infection control protocols
including wearing gloves, mask, and gown as indicated.
Acupressure will not be performed when there is skin
breakdown or performed only on unaffected areas.
Patients are treated in their clothing or hospital
gowns either lying in bed or seated in a chair according
to patient preference. Lotion is not used. To assess
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intervention fidelity, randomly selected sessions are
observed by study investigators.
Parent acupressure intervention. Caregivers are trained by
the acupressure providers in the performance of acupres-
sure for the patient. The training occurs at the same time
as the professional acupressure intervention is initiated.
Parents are encouraged to provide acupressure on a
daily basis or as requested by the child. Teaching mate-
rials include a brochure with instructions including pic-
tures of each point, a description of recommended points
for each symptom, and point names (in English and
Chinese). Video teaching instructions are also available
on the study website for parents in Arm A (using a
website log-in). During the first week of regular child
acupressure, the provider begins by teaching parents
the safety precautions and acupressure points for specific
symptoms (eg, nausea, vomiting, pain, and fatigue).
Teaching is updated each time the acupressure provider
gives a session until parents are confident. Parents in
Arm B (controls) are given acupressure instructions
and materials when they complete the study.
Usual care for symptom management applied to both groups.
Usual care is defined according to Children’s Oncology
Group endorsed supportive care guidelines for nausea
or vomiting54 with updated guidelines7,96–100 and
guidelines for management of pain101 and fatigue.102
Usual care for symptom management to reduce
nausea and vomiting involves the classification of the
antineoplastic agents into varying levels of emetogenic-
ity (highly emetogenic chemotherapy [HEC], moder-
ately emetogenic chemotherapy [MEC], low and
minimal emetic risk) and the provision of appropriate
antiemetic agents on a regular schedule. The goal is to
achieve optimal control of acute CINV, defined as “no
vomiting, no retching, no nausea, no use of antiemetic
agents other than those given for CINV prevention, no
nausea-related change in the child’s usual appetite and
diet.”103 Different antiemetic agents are recommended
based on the age of the child, treatment factors (ie,
avoidance of drug interactions), and the emetic risk.
Guidelines to treat anticipatory and breakthrough
nausea and for the prevention of refractory nausea
are also followed.7,99
Discontinuation of Intervention
The intervention will be discontinued if continued par-
ticipation is no longer in the patient’s best interest (ie, in
Table 1. Summary of the Semistandardized Intervention Details.
Acupuncture rationale:
Style of acupuncture and
reasoning for treat-
ment provided
The intervention is a semi-standardized acupressure protocol based on TCM theory. From a
Western medical perspective, chemotherapy-related symptoms are associated, with inflammatory
processes.13,14,67,68 Acupuncture acts on the neuroendocrine system69 or through anti-inflammatory
effects.70–75 TCM will be used with points chosen based on peer reviewed research, TCM texts, and
consensus of licensed acupressure provider experts (see Appendix 1).
Point stimulation details:
Number of points, names,
and technique of
stimulation
The practitioner takes a history, feels the patient’s pulse, observes the tongue, forms a TCM diagnosis, and
chooses from a platform of points and additional points (listed in Table 2). A mean of 6 acupoints (range
2–10) unilateral and bilaterallya are stimulated using fingers for 3 minutes each using a pressing and
circling motion until di qi is achieved.
Parent acupressure can be offered daily, 3 minutes per point for 2 points bilaterally using similar
techniques.
Treatment regimen:
number, frequency, and
duration of sessions
Approximately 20 (15–20 min) professional sessions are offered to participants over 30 study days.
Sessions are offered 5 days/week.
Acupressure providers record delivery of the intervention including symptoms treated and points stim-
ulated. If a participant does not receive the intervention the reason is recorded. Data is collected for
each intervention.
Other components
of treatment
No other components of the acupressure intervention.
Practitioner qualifications Licensed acupuncturist trained in TCM.
2þ years of acupuncture clinical experience.
Successful completion of supervised clinical internship.
Successful completion of exam by State of California Acupuncture Board or Acupuncture MD training.
Rationale and description
of control group
intervention
The control group receives usual care for symptom management. Participants will not be coenrolled
in studies testing the effectiveness of antiemetics or studies testing the effectiveness of massage or
acupuncture. While enrolled in the ACT-CC study families agree to refrain from non-study-related
massage, acustimulation, TENS units, and sea band use unless medically indicated.
Abbreviations: ACT-CC, Acupressure for Children in Treatment for a Childhood Cancer; TCM, Traditional Chinese Medical; TENS, Transcutaneous
Clectrical Nerve Stimulation.
aBarriers to use of bilateral points include limb amputation and medical equipment obstructing access.
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response to an adverse event as needed; emergence of
skin breakdown due to GVHD), upon patient or care-
giver request, when exclusion criteria occurs (even mid-
enrollment) or in the case of concurrent illness that
prevents acupressure from being delivered (ie, when a
patient is moved to the Pediatric Intensive Care Unit).
Intervention Fidelity
The principal investigator (PI) does periodic observa-
tions of the acupressure providers for fidelity to the writ-
ten intervention protocol.
Outcomes
Patient-Reported Outcomes Measurement Information
System (PROMIS) measures are used when available con-
sistent with the study interest in patient-reported outcomes
(PROs). They are valid, easily understood and inter-
preted,104 comparable across studies, often used in clinical
trials,105 demonstrate strong reliability (.85) for each
domain measured,106–108 and when a repeated measure,
are responsive to changes in status in pediatric cancer
patients109 and in adults.110 Both adult and pediatricmeas-
ures are designed for those with chronic health conditions
(as well as general populations), aged 8 to 17 years,111 and
child proxy measures can be filled out by parents to assess
symptoms in children aged 5 to 7 years or when children
are unable to fill out forms.103,112 Studies have verified the
feasibility and efficiency113 of administering PROMIS
instruments via tablet computers (see Table 3).114
Additional data related to child outcomes are col-
lected from the electronic medical records (EMRs)
including supportive care pain and antiemetic medica-
tions; medications for sleep; vomiting episodes; pain;
ability to drink; parenteral nutrition; fever; chemother-
apy complications (infection/sepsis, bleeding, GVHD,
or hepatic veno-occlusive disease). Laboratory data
being collected include the absolute neutrophil count
(ANC) and platelet count. Additional information will
be collected on likely precipitants for nausea/vomiting
including chemotherapy (agent, dose, timing), surgery
Table 2. Points for Each Symptom/TCM Diagnosis.
Symptom(s) TCM Diagnosis AcuPointsa
Nausea and
Vomiting23,41,49,50,52,56,78–83
Rebellious Stomach Qi (this diag-
nosis applies to all
nausea/vomiting)
Platform Points: P6 ! SP4 ! ST36 ! REN 12
Excess Condition: Accumulation of
Heat, Cold or Food in Stomach
(þ) ST44/Nei Ting (extra point) ! ST41 ! GB34
Deficient Condition: Spleen Qi Def (þ) UB20 ! Ren 6 ! ST25
Deficient Condition: Stomach
Yin Def
(þ) KI6 ! UB21 ! Ren4
Pain61,84–90 Qi and Blood Stagnation in the
Channel (true for most cases)
Platform Points: LV3 ! HT7 ! LI4
Head Pain (þ): LI4 ! SJ5 ! GB41
Chest Pain (þ): P6 ! Ren 17 ! KI27 ! LU1
Stomach Pain (þ): UB 40 ! ST36 ! REN12
Hypochondria Pain (þ): SJ5 ! GB34 ! LV8 ! LV14
Upper Limb Pain (þ): LI4 ! LI11 ! LI15
Lower Limb Pain (þ): ST40 ! GB34 ! SP10
Fatigue15,38,39,51,85,89,91–93 Deficiency of Qi, Blood, Yin, Yang Platform Points: SP6 ! ST36 ! DU20
Qi Deficient (þ): LU9 ! UB13 ! REN6
Blood Deficiency (þ): HT7 ! SP4 ! LV8 ! UB17 !
UB18
Yin Deficiency (þ): LU7 ! KI6 ! UB23
Yang Deficiency (þ): KI7 ! UB23 ! DU14
Depression38,85,89,91,94 Excess Diagnosis: Liver
Qi Stagnation
Platform Points: LI4 ! P6 ! LV3
Deficient Diagnosis: Deficiency of
Qi, Blood, Yin, Yang
Platform Points: SP6 ! ST36 ! DU20
Anxiety38,39,85 Excess Diagnosis: Qi Stagnation Platform Points: Ki1! HT7! P6! Yintang! Du20
Deficient Diagnosis: Deficiency of
Qi, Blood, Yin, Yang
Platform Points: SP6 ! ST36 ! DU20
General Well-Being38,95 Platform Points: LU7 ! LI4 ! LI11 ! SP6 ! ST36
Additional Points: KI1 ! Yintang ! DU2
Abbreviations: TCM, Traditional Chinese Medical; þ, additional points that can be used to supplement the platform of points.
aParents only use bolded points.
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Table 3. Study Child and Parent Outcomes.
Measure Description Frequency
Primary Child Outcome
Demographic and
other covariates
Age, sex, race, ethnicity, highest years of education, socioeconomic status,
family structure, siblings (number and ages), and single parenthood,115
diagnosis, COG study protocol.
Baseline
Nausea/vomiting Composite measure capturing the continuum of nausea/vomiting with a
range of 1 to 8. The raw number will be assessed. The measures are
defined for 2 age groups.
Daily
PeNAT and vomit-
ing question
Among children age 5 to 17, nausea is measured using the PeNAT116 which
is validated for ages 5 to 17. The 1 to 4 scale¼ none, mild, moderate, and
severe using faces is a preferred method of measuring distress among
children.117 Daily vomiting is assessed with one question (no. of episodes
1 min apart) with a range of 0 to 4þ, capped at 4.118,119
Daily
MAT For young adults ages 18 to 24, the MAT is used to assess both nausea and
vomiting domains.120 MAT nausea responses are on a 0-10 scale and can
be re-categorized on a 1 to 4 scale for comparability. The MAT nausea
question has been adapted by deleting the phrase “. . . since your last
chemotherapy” given the current study is interested in nausea and vom-
iting from any source. The number of MAT vomiting episodes are
recorded and later capped so the range will be 0 to 4þ episodes in a 24-
hour period. Together, the scale represents a continuum from complete
control (value¼ 1), partial control (value¼ 2–4), and severe nausea and
vomiting (value¼ 5–8).
Daily
Secondary Child Outcomes
PeNAT, MAT, and vomiting These measures will be used separately as secondary outcomes
(described above).
Daily
Pain interference
and intensity
PROMIS: 4 items assess pain interference,108 and a single item assesses pain
intensity121 in children ages 8þ.
Daily
Faces Pain Intensity FPS-R: 1 item assesses pain in children ages 5 to 7.122 Scores range from 0 to
10.123–127
Daily
Fatigue PROMIS: 4 items assess fatigue.128 Twice/week
Depression, anxiety PROMIS: 4 items each assess depression and anxiety.107 Once/week
Positive affect PROMIS: 4 items each assess well-being.129,130 Once/week
SSPedi SSPedi is a pediatric cancer-specific symptom screening and assessment scale
measuring physical and psychological symptoms (eg, feeling angry, sad or
worried, tired, mouth sores, headache, constipation or diarrhea, prob-
lems thinking or remembering, body changes, or appetite loss, among
others) in 15 questions.131–133 with a proxy version.134 The SSPedi is also
used in a pediatric HSCT population.4 This instrument provides a brief
measure of the most burdensome pediatric symptoms with minimal
respondent burden.
Twice/week
Prior and current acusti-
mulation exposure
Children age 10þ are asked about child’s previous experience with acusti-
mulation at baseline. Parents are asked about same when for children age
5 to 9 years. At the final interview data on exposure to acustimulation or
massage from nonstudy providers during study enrollment will be col-
lected including number of times and symptoms treated.
Baseline and
final
interview
Acupressure expectations Will be assessed at baseline consistent with previous research28 scoring on a
5-point scale with 1¼ not at all effective and 5¼ very effective. Treatment
outcome expectations have been reported to influence outcomes.135,136
Baseline, at 1
week, and
final
interview
Rescue pain and
antiemetics
Extracted from EMR. Daily
Parent Outcomes: parents receive baseline, week 1 and a final survey
Demographics For child, parent, and household Baseline
Prior experience Parents are asked about child’s prior experience with acupuncture. Baseline
Acupressure expectations
(continued)
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(length of surgery, length of time since surgery, and
body location), and investigational drugs. Related to
the timing of treatment, variables will be created based
on the following conditions: CINV will be categorized
for children reporting nausea during administration
and up to 24 hours following chemotherapy.151,152
For delayed CINV, we will analyze CINV scores in
groups (HEC, MEC, vs lower intensity) up to 4 days
after the end of chemotherapy administration based on
recommendations from a National Institute for Health
Research report.151 For PONV, we will categorize a
participant at risk for nausea/vomiting following sur-
gery for up to 24 hours.153
Participant Timeline
Table 4 details the participant timeline.
Sample size. The target sample size is 85 participants
along with 85 parents/caregivers. Participants are ran-
domized on a 1:1 basis into each of the 2 study arms.
Under some simplifying assumptions, detailed below, we
estimate that this sample of 85 patients, randomized 1:1
to acupressure versus usual symptom management,
will provide 80% power in 2-sided tests with a of .05
to detect average reductions of 0.52 to 0.58 standard
deviations (SDs) in pairwise comparisons between the
Table 3. Continued.
Measure Description Frequency
Four questions each on expectations of effectiveness of the professional
acupuncture and the parent performed acupressure are included.137
Baseline and
week 1
Depression and anxiety PROMIS 4 item depression and 4 item anxiety measures from the PROMIS
Adult Profile Bank.138,139
Baseline,
week 1
and final
PANAS Positive Affect Subscale of the PANAS (5-items): This positive affect sub-scale of
the 10-item PANAS scale (i-PANAS-SF) assessed positive or pleasurable
engagement with the environment, well-being, and satisfaction with life.
The scale can be used cross-culturally and has acceptable internal reli-
ability, temporal stability, convergent, and criterion-related validity.140 A
Spanish translation is available. A translation exists for the full 20 item
version141 and the study translator used that version to create the
shorter 5-item Spanish version.142
Baseline, 1
week
and final
PTSS Posttraumatic stress disorder Checklist (PCL-5) (20 items): updated to meet
DSM5 criteria, responses assess frequency and intensity of symptoms
(strong internal consistency, test-retest reliability and validity).143
Baseline
and final
PSES Parent’s Self-Efficacy Scale (PSES)144 (6 items): adapted from Bandura145 and
Lorig,146,147 and previously used in parents of children with disabilities
(excellent psychometric reliability and validity).144,148
Baseline
and final
Parent delivered
acupressure
Parent-delivered acupressure data: frequency, duration, acupoints used, and
child symptoms being treated.
Daily
Acupressure expecta-
tion-met?
One item assesses whether acupressure expectations were met using
5-item Likert scale.
Final
Patient satisfaction Two items assess satisfaction with hospital stay149 and with intervention150 Final
Experience (open-ended) One open question asked at the final interview: “Can you tell us in a few
words how it was for you to learn and do acupressure on your child?
Final
Rewards and burden Parent rewards and burdens of delivering acupressure: 2 questions use Likert
scale to assess parent reward and burden in delivering acupressure.
Final
Acupressure Provider Information
Intervention details The acupressure provider documents each session: chief complaint/symp-
tom, secondary complaints, observation of the pulse and tongue, TCM
diagnosis, points used, total minutes of acupressure, and patient response.
The provider also asks parents about delivery of acupressure to their
child: minutes of acupressure delivered each day, points used, symptoms
treated, and child’s reaction.
At each
interven-
tion
session
Abbreviations: COG, Children’s Oncology Group; EMR, electronic medical record; FPS-R, Faces Pain (Intensity) Scale-Revised; HSCT, hematopoietic stem
cell transplant; MASCC, Multinational Association of Supportive Care in Cancer; MAT, MASCC Anti-emesis Tool; PeNAT, Pediatric Nausea Assessment
Tool; PANAS, positive and negative affect schedule; PROMIS, Patient-Reported Outcomes Measurement Information System; PTSS, posttraumatic stress
disorder Checklist; SSPedi, The Symptom Screening in Pediatrics; TCM, Traditional Chinese Medical.
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acupressure arm and the usual care only arm, depending
on the intraclass correlation (ICC) of the repeated out-
come measures (assumed to be 0.6–0.8). (With a more
conservative assumption where ICC¼ 0.9, the minimal
detectable effects [MDE] would increase to 0.61.)
MDEs in context. In a systematic review of acupressure
studies of CINV, the standardized ES for vomiting epi-
sodes was 0.53 SDs, for retching episodes ES¼ 0.44 SDs,
for severity of nausea, ES¼ 0.73 SDs, for the use of
rescue antiemetics ES¼ 0.46 SD’s,35 child-reported
pain ES¼ 0.42 SDs, and fatigue ES¼ 0.78 SDs.90 A
composite score for nausea/vomiting should fall within
the ES range for CINV in previous studies. Additional
ESs for secondary symptoms fall within a similar range
where pain ES¼ 0.37–0.55.93 Thus, our calculations sug-
gest that, in the case where the ICC¼ 0.6, with a sample
size of 85 we expect to have 80% power to detect plau-
sible and clinically significant effects for nausea,
vomiting, and fatigue outcomes and may be able to
detect differences in pain. If the ICC¼ 0.8, we expect
to be able to detect differences for nausea and fatigue.
Recruitment. Patients are identified and recruited at
varying stages of their disease course: at the time of
diagnosis; during a new or repeat hospitalization, mid-
treatment, or at relapse.
The study nurse monitors all planned and unplanned
admissions and outpatient appointments, and prescreens
for eligibility including age, diagnosis, language, and
availability of a parent/caregiver. Approval of a treating
health-care provider is sought before eligible patients are
approached during inpatient or outpatient visits to the
hospital. Consent is obtained from parents/caregivers
and patients who are 18 years and older, and assent is
obtained from patients aged 8 to 17 years following
UCSF institutional review board (IRB) guidelines (see
Figure 1).
Figure 1. Research design schema.
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Methods: Assignment of Interventions for
Controlled Trials
Randomization, Allocation Concealment Mechanism,
and Blinding
After collection of baseline data, the study nurse (who
does not see study patients) performs 1:1 simple random-
ization into 2 groups: acupressureþusual care versus
usual care alone using a Qualtrics computer-based
assignment program in which the study nurse enters
the participant ID number before randomization is
revealed. Assignment is immediately locked into the
database. Study staff who carry out the symptom assess-
ments and health-care providers are blinded to study
arm assignment. The use of simple randomization is con-
sidered the strongest design to prevent selection bias.154
The acupressure provider, floor nurses, patients, and
caregivers are not blinded due to the type of interven-
tion. Floor nurses are informed before the acupressure
provider enters the room to ensure that there are no
medical issues that need to be addressed. Families are
asked not to disclose their study arm to the staff and
periodic checks assure us that the physicians remain
unaware of allocation. Allocation is communicated to
the family by the acupressure provider who naturally
knows the allocation.
Methods: Data Collection, Management,
and Analysis
Data Collection
Study staff were trained in the collection of survey data.
Data are monitored post interview for accuracy and
completeness. Survey data collection can occur in 4
ways: paper survey administered by staff, paper survey
filled out by patient or parent, staff administered assess-
ment using a portable device (ipad) with a link to a
programmed questionnaire, or patient/parent filling
out survey using link to the online questionnaire. See
Table 3 for survey outcomes and timing. Study assess-
ments are allowed a window of 3 weekdays, 4 days
between consent and baseline, and 10 days for final
surveys. Electronic Medical data for each patient partic-
ipant for each study day are collected using digi-
tal methods.
Patient retention is promoted by efforts of study staff
to form a trusting relationship with participants, the use
of a financial incentive of $50 each (caregiver and child)
upon study completion, and, for the control arm, by
providing instruction and training for caregivers to
deliver acupressure at the end of participation.
Data Management
Survey data are entered into the Qualtrics database and
recruitment and enrollment tracking data are recorded
and stored using secure HIPAA compliant software. The
study project manager monitors data entry for accuracy
and completeness for both sites. Survey data include
study ID with no protected health information (PHI)
with the exception of the baseline and follow-up
survey. Baseline and follow-up surveys are deidentified
before the analysis phase. Information linking the study
ID and patient PHI are kept in a HIPAA secured envi-
ronment separate from survey data. Physical records are
kept in an area accessible only to research staff and in a
locked file cabinet. No names or individual identities will
be used in publications resulting from the study.
Research data are stored on a secure, HIPAA-
compliant server and drive with monitored and con-
trolled access for study staff and investigators.
Statistical Analysis
Aim 1: Child Outcomes
Summary of proposed modeling approach. This study will use
linear mixed models (LMMs), an extension of least
squares regression to longitudinal data. Among other
advantages, this approach will accommodate differences
in treatment timing, intensity and emetogenicity between
the treatment groups, and differences related to treat-
ment uptake and the semistandardized intervention,
while also accounting for within-patient correlation of
repeated measures, optimally weighting data for patients
with different numbers of responses, and providing valid
estimates in the presence of missing data under relatively
mild assumptions about how the missing data arise.155
In brief, we will flexibly model the time course of the
composite nausea/vomiting severity scale for each treat-
ment group and by emetogenicity, which will allow us to
estimate average differences between these trajectories
by randomized study intervention assignment (acupres-
sure vs usual care). The model will intrinsically weight
patients in proportion to the length of the course
of treatment.
Technical description of analysis approach. We will flexibly
model the average time course of composite nausea/
vomiting scores (and severity of symptoms for other out-
comes) for each combination of treatment modality and
intervention assignment, using group-specific restricted
cubic splines (RCS) in time since the start of study
enrollment. The model will also include random inter-
cepts and RCS components, to flexibly model patient-
specific departures from the average group-specific
trajectory. In addition, to capture spikes in symptom
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severity in the first few days after surgery or chemother-
apy, the model will include time-dependent covariates
flexibly modeling the effect of time since the most
recent chemotherapy, surgery, and/or radiation, depend-
ing on the outcome (ie, for CINV chemotherapy will be
dominantly factored in). The function of these adjust-
ments is to explain variability in the outcome, increasing
model efficiency. Normalizing transformation of the
composite nausea/vomiting symptom severity scale will
be used if necessary. We will assess the adequacy of both
the fixed and random parts of the model and check for
modification of the effects of the acupressure by both
time and treatment modality. We will perform intent-
to-treat analyses (by original assigned groups), which is
the recommended method for describing clinical trial
results,65 and additional analyses will report on groups
as treated.
Assumptions and sensitivity analyses. This approach relies on
the plausible assumption that the timing and duration of
treatment will not be affected by assignment to or inten-
sity of the use of acupressure. Sensitivity analyses will be
conducted assessing evidence for violations of this
assumption, using between-arm comparisons of treat-
ment patterns, as well as models for the association of
lagged acupressure intensity with the timing of subse-
quent treatments.
Dose–response analysis using marginal structural models (Aim
1). Our primary analyses for each symptom will be by
intent-to-treat, according to allocation assignment, with-
out regard to the intensity or duration of acupressure
actually received. To assess dose effects as an explorato-
ry analysis, the effects of total minutes of professional
acupressure (as well as total minutes of professional plus
caregiver provided acupressure) received per week,
treated as an ordinal category with 3 to 4 levels, will
be estimated in a secondary analysis. Because acupres-
sure duration may depend on earlier levels of the out-
come, marginal structural models will be used.
Aim 2: Parent Outcomes
We will determine whether parents differ in posttrau-
matic stress symptoms (total symptom scores), depres-
sion, and anxiety (T scores) and caregiver self-efficacy
(score) between groups at 2 points: at week 1 for both
arms regardless of pattern of hospital-based treatment;
and at 1 month post-study enrollment, which will vary
depending on whether patients have 1 month of contin-
uous hospitalization followed by 1 month for follow-up
or intermittent hospitalization or outpatient treatment
over 2 months followed by a 1 month follow-up. In
both cases, analysis will control for baseline values as
appropriate. We will use similar analytic approaches as
in Aim 1, with LMM as the primary analysis approach.
Exploratory analysis of heterogeneity of treatment effects.
Using LMMs we will explore heterogeneity of treatment
effects by demographics (age, sex, race/ethnicity), diag-
nosis, treatment agent/modality, or initiation of most
recent treatment dose, with the goal of assessing varia-
tion in benefit from acupressure by subgroup. Our over-
all hypothesis in regard to heterogeneity of treatment
effect is that groups with more severe symptoms of
nausea and vomiting will experience greater benefit.156
If certain groups benefit more from acupressure, recom-
mendations may target provision of the intervention to
these groups. Given our anticipated sample size of
n¼ 85, within-subgroup effect estimates will likely have
wide confidence intervals, and power to detect between-
subgroup differences may be low. Since previous
research has not documented point estimates for differ-
ences between subsamples within pediatric populations,
these findings will provide preliminary estimates of ESs
within subgroups which will be the basis for future stud-
ies of subsamples.
Missing Data Approaches
Some outcome data may be missing not at random
(MNAR)—in particular, when missing symptom assess-
ments occur due to early hospital discharge, moving into
hospice care, severe symptoms or illness, refusal to
answer, or conflicts with other medical procedures. To
address this difficulty, we will perform sensitivity analy-
ses using multiple imputation of missing outcomes under
plausible MNAR scenarios as well as under the standard
MAR assumptions for key outcomes. Where feasible, we
will utilize appropriate information on nausea, vomiting,
and pain available in the EMR in multiple imputation
models to take advantage of data that may be available
even when patient-reported symptom data cannot be
collected directly.
Definition of populations. Intent to treat is defined as the
entire randomized sample.
Methods: Monitoring
Data Safety Monitoring and Audits
The study is monitored by the Helen Diller Family
Comprehensive Cancer Center (HDFCCC) Regulatory
Unit for quality and regulatory compliance with yearly
audits of 20% of participants (guideline for minimal risk
trial) and biannual review by the Data Safety
Monitoring Board (DSMB) reporting on data quality,
subject safety, serious adverse reactions, and yearly
Lown et al. 11
accrual. The DSMB is independent from PCORI and the
Investigators have no competing interests. The DSMB is
made up of members who are knowledgeable in the con-
duct of research, with backgrounds in cancer, biostatis-
tics, experimental design, or bioethics. The HDFCCC
DSMB charter can be found at http://cancer.ucsf.edu/
itr/itr-dsm.
Interim Analyses and Stopping Rules
The primary clinical outcome variable, nausea/vomiting,
is a symptom associated with exposure to pediatric cancer
treatment and HSCT conditioning. Continued nausea/
vomiting is not an outcome that would justify early ter-
mination rules for a study of this nature, and it is highly
unlikely that there would be differences in mortality or
any other major health difference between arms. No inter-
im analyses related to outcome will be performed and we
do not anticipate stopping the trial early.
Adverse Events
Any adverse events (AEs) related to the administration
of acupressure, specifically including bruising or skin
irritation, are recorded. AEs can be reported by the
family or the medical provider. All AEs are entered
into the study records. Study AEs are graded. Serious
(grade 3 and above) AEs are reported to IRB and the
DSMB. AEs are monitored and discussed at every study
staff and Co-Investigator meeting.
Ethics and Dissemination
The ACT-CC study has been approved by UCSF Helen
Diller Family Comprehensive Cancer Center Protocol
Review Committee and the IRB at UCSF Benioff
Children’s Hospital Mission Bay site (9-26-17) and
Benioff Children’s Hospital-Oakland site (11/3/17).
HIPAA permissions, Patient Bill of Rights and con-
sent/assent is obtained by trained study staff who receive
6 weeks of Cancer Center training in addition to training
from the PI. No biological samples are collected for
this trial.
This study includes a vulnerable population of chil-
dren with life-threatening conditions. Thus efforts are
made to reduce patient burden in the following way:
after baseline regular assessments are short (<5min)
and enrolled patients can decline acupressure sessions
or assessments; parents in Arm A are taught to provide
acupressure and training is available throughout enroll-
ment; surveys can be performed using the most conve-
nient survey method. A pediatric cancer or HSCT
population can be challenging to access given severe
symptoms, fatigue, the need to have both the child and
parent present for consent and intervention delivery for
the youngest group, and the need to work around curative
treatment procedures, medical equipment, and health-
care personnel visits to the room. Thus, study staff receive
training and ongoing monitoring as recruitment and
enrollment occurs to ensure that patient needs are hon-
ored and study procedures are transparent, clear, and
optional. Acupressure training is provided to caregivers
in the control arm after the family finishes the trial to
ensure that everyone enrolled has the opportunity to ben-
efit from the intervention if desired. We ask participants
to refrain from receiving acupuncture, acupressure or
massage from outside providers during the trial unless
medically indicated, in which case, patients can remain
in the trial and receive integrative medicine services. The
use of integrative medicine services is documented.
Protocol changes related to eligibility or any signifi-
cant change in study procedures are reported to the
study funder, the HDFCCC Site Committee, the IRB,
and updated on clinicaltrials.gov.
Study results will first be presented to our stakehold-
ers for evaluation and discussion. After incorporating
stakeholder feedback, final study results related to pri-
mary and secondary outcomes will be published in peer-
reviewed journals and presented at one or more scientific
conferences.
Confidentiality
At recruitment, personal information is collected
through secure e-mails (to get treating health-care pro-
vider permission to approach). Enrollment tracking is
recorded using HIPAA compliant software or stored in
HIPAA compliant secure folders. No names or personal
identifiers are available during the analysis phase.
Access to Data
Access to the data involves a formal request including an
abstract, proposed aims, background, outcomes, analy-
sis plan, and investigator qualifications. Upon approval
a complete, cleaned, and de-identified copy of the final
dataset will be provided. Data sharing will be coordinat-
ed to avoid overlapping analyses.
Discussion
The results of the ACT-CC trial will provide both feasi-
bility and effectiveness data so that Hematology-
Oncology and HSCT treatment centers can assess the
logistics, risks, and benefits of integrating acupressure
into symptom management along with usual care in
inpatient and outpatient settings treating childhood
cancer or providing a chemotherapy-based HSCT. To
our knowledge, this study represents the largest study
employing a semistandardized daily acupressure inter-
vention for pediatric oncology and HSCT-patients.
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In 2002, the NIH convened a 14-member multidisci-
plinary expert panel to examine symptom management
dilemmas for patients with cancer.157,158 The panel
stated that all patients should have optimal symptom
control throughout the course of their illness and sug-
gested that pain, depression, and fatigue are inadequate-
ly treated in most cancer patients. Additional data show
that effective management of nausea and vomiting in
children remains challenging.3,96 This trial will provide
data on an integrative medicine approach to improve
symptom management.
Although the trail has employed rigorous methodol-
ogy, nonetheless, it has limitations. A sample size of 85
may make it harder to detect differences between groups
for pain. It is likely to be difficult to determine the effec-
tiveness of the intervention between subgroups such as
those receiving inpatient versus outpatient care,
hematology-oncology versus HSCT, by age, or by diag-
nosis. A future larger multisite trial would be important
to increase the sample size so that the effectiveness in
subgroups could be explored in more depth.
Trail Status
The trial is currently active enrolling and was opened in
October 2017. No posttrial care is required.
Appendix 1
A Clinical Review Team including experts in the field
convened at the Acupuncture and Integrative Medicine
College, Berkeley (AIMC). The team was organized by
Robyn Adcock and included the following experts who
reviewed the protocol and provided additional feedback.
Robyn Adcock and Michael Morgan are the acupressure
providers for the ACT-CC study.
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